Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies.
| Autor: | Kiran NS; Department of Biotechnology, School of Applied Sciences, REVA University, Bengaluru, Karnataka 560064, India., Yashaswini C; Department of Biotechnology, School of Applied Sciences, REVA University, Bengaluru, Karnataka 560064, India., Maheshwari R; School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Green Industrial Park, TSIIC,, Jadcherla, Hyderabad 509301, India., Bhattacharya S; School of Pharmacy and Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India., Prajapati BG; Shree. S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, Gujarat 384012, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2024 Mar 19; Vol. 7 (4), pp. 967-990. Date of Electronic Publication: 2024 Mar 19 (Print Publication: 2024). |
| DOI: | 10.1021/acsptsci.4c00008 |
| Abstrakt: | Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels. Competing Interests: The authors declare no competing financial interest. (© 2024 American Chemical Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|